SALT LAKE CITY, Apr 19, 2010 (GlobeNewswire via COMTEX News Network) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man's risk of prostate cancer recurrence after radical prostatectomy.
The PTEN gene is one of the most important tumor suppressor genes discovered to date and is mutated in a large number of cancers at a very high frequency. Details of the study were presented today at the 2010 meeting of the American Association for Cancer Research (AACR) in Washington D.C. The presentation is entitled: "PTEN Expression Predicts Biochemical Recurrence in Prostate Cancer," and the abstract (Number: 1186) is available on the AACR website at www.aacr.org.
The study examined prostate tumor tissue from 132 patients for which 5-year follow-up data were available following prostatectomy surgery (removal of the prostate gland and some surrounding tissue). PTEN protein expression was determined by immunohistochemisty (IHC), and was predictive of biochemical recurrence of prostate cancer in this patient group (p-value = 0.0046). In addition, the analysis of the PTEN gene and the loss of PTEN function was predictive of patient survival outcome at a statistically significant level after adjusting for tumor stage (p-value = 0.009), suggesting that PTEN status provides additional prognostic information not otherwise available to physicians.
"These exciting scientific findings provide further evidence of the important role the PTEN gene plays in prostate cancer," commented Jerry Lanchbury, Ph.D., Chief Scientific Officer at Myriad Genetics. "PTEN also shows promise in numerous other cancer types and we look forward to future studies that will further extend this gene's potential clinical utility."
About Prostate Cancer
In the United States, approximately 80,000 men undergo a radical prostatectomy each year. Approximately 35% of those men will eventually have a biochemical recurrence indicating the return of their cancer. Molecular markers designed to offer urologists an accurate and objective way of determining an individual's recurrence risk, beyond current clinical assessment techniques, should have significant clinical utility. Patients at higher risk of recurrence are candidates for more intensive screening and therapeutic strategies given the aggressiveness of their cancers. Patients at lower risk of recurrence are good candidates for less frequent and intrusive observation.
About Myriad Genetics
Myriad Genetics, Inc. is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G
The Myriad Genetics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6336
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of the PTEN study results at the American Association for Cancer Research; the utility of the PTEN gene in predicting prostate cancer recurrence; the clinical utility of the expression of the PTEN gene in assessing a man's risk of prostate cancer recurrence after radical prostatectomy; the importance of the PTEN gene as a tumor suppressor gene and the number of cancers in which it is mutated; the suggestion that PTEN status provides additional prognostic information not otherwise available to physicians; the importance of the role the PTEN gene plays in prostate cancer; the belief that PTEN also shows promise in numerous other cancer types; and the Company's anticipation that future studies will further extend the PTEN gene's potential clinical utility. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic products may decline or will not continue to increase at historical rates; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic products in a timely manner, or at all; the risk that licenses to the technology underlying our molecular diagnostic products and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over our products; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our products; the risk of patent-infringement claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2009,which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Myriad Genetics, Inc.
CONTACT: Myriad Genetics, Inc. Suzanne Barton, Director, Investor Relations (801) 584-1138 email@example.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX